Loading
Following 1,180 men for more than twelve years, and then pooling 48 other studies, found that the commonest genetic change in prostate cancer does not predict who does badly.
Among men with prostate cancer in the prospective Physicians' Health Study and Health Professionals Follow-Up Study, rearrangement status was determined by immunohistochemical assessment of ERG protein expression, and Cox models examined associations with biochemical recurrence and lethal disease, defined as distant metastases or cancer-specific mortality. The cohort consisted of 1,180 men treated with radical prostatectomy between 1983 and 2005; during a median follow-up of 12.6 years, 266 men experienced recurrence and 85 developed lethal disease. There was no significant association between ERG overexpression and biochemical recurrence, hazard ratio 0.99, or lethal disease, hazard ratio 0.93. A meta-analysis including 47 additional studies covered 5,074 men followed for biochemical recurrence with 1,623 events and 2,049 men followed for lethal disease with 131 events; TMPRSS2-ERG was associated with stage at diagnosis, risk ratio 1.23 for T3 or above against T2, but not with biochemical recurrence, risk ratio 1.00, or lethal disease, risk ratio 0.99.
It is the definitive negative result for the commonest genomic alteration in this disease. A man told his tumour carries the TMPRSS2-ERG fusion should be told plainly that it does not make his cancer more dangerous.
Shares TMPRSS2, TMPRSS2-ERG fusion (and the other ETS rearrangements), ERG, Prostate cancer (KEGG map).
Shares TMPRSS2, TMPRSS2-ERG fusion (and the other ETS rearrangements), ERG, Prostate cancer (KEGG map).
Shares ERG, Prostate cancer (KEGG map), Androgen receptor signalling, Gene fusion.
Shares TMPRSS2-ERG fusion (and the other ETS rearrangements), Prostate cancer (KEGG map), Androgen receptor signalling, Gene fusion.
Shares TMPRSS2, ERG, Prostate cancer (KEGG map), Androgen receptor signalling.
Shares Prostate cancer (KEGG map), Immunohistochemistry (IHC), Histopathology & immunohistochemistry, Prostate cancer.
Shares TMPRSS2, TMPRSS2-ERG fusion (and the other ETS rearrangements), ERG, Prostate cancer (KEGG map).
Shares TMPRSS2, ERG, Prostate cancer (KEGG map), Androgen receptor signalling.